Table 2.
Percentage of children with anti-measles, mumps and rubella antibodies in initially seronegative children (ATP cohort for persistence).
| Group | Timing | N | n | % (95% CI) | GMC (95% CI) |
|---|---|---|---|---|---|
| Anti-measles antibody ≥200 mIU/mL | |||||
| MMR-RIT-1 | D42 | 182 | 181 | 99.5 (97.0−100) | 2779.3 (2509.9−3077.7) |
| Y1 | 179 | 178 | 99.4 (96.9−100) | 3230.2 (2820.4−3699.7) | |
| Y2 | 171 | 171 | 100 (97.9−100) | 3361.1 (2922.3−3865.6) | |
| MMR-RIT-2 | D42 | 172 | 169 | 98.3 (95.0−99.6) | 3010.1 (2669.0−3394.7) |
| Y1 | 175 | 172 | 98.3 (95.1−99.6) | 3766.9 (3245.6−4372.0) | |
| Y2 | 159 | 159 | 100 (97.7−100) | 3963.8 (3479.3−4515.7) | |
| MMR-RIT-3 | D42 | 186 | 184 | 98.9 (96.2−99.9) | 2703.0 (2446.6−2986.3) |
| Y1 | 191 | 191 | 100 (98.1−100) | 3521.5 (3094.6−4007.3) | |
| Y2 | 169 | 168 | 99.4 (96.7−100) | 3360.3 (2923.3−3862.7) | |
| M-M-R II | D42 | 178 | 177 | 99.4 (96.9−100) | 2749.6 (2469.9−3061.0) |
| Y1 | 178 | 177 | 99.4 (96.9−100) | 3930.4 (3423.3−4512.7) | |
| Y2 | 166 | 166 | 100 (97.8−100) | 4022.1 (3507.7−4611.9) | |
| Anti-mumps (PPD ELISA) ≥10 ELU/mL | |||||
| MMR-RIT-1 | D42 | 159 | 152 | 95.6 (91.1−98.2) | 56.8 (48.7−66.3) |
| Y1 | 141 | 127 | 90.1 (83.9−94.5) | 47.0 (37.9−58.2) | |
| Y2 | 136 | 128 | 94.1 (88.7−97.4) | 47.8 (40.2−56.9) | |
| MMR-RIT-2 | D42 | 153 | 142 | 92.8 (87.5−96.4) | 43.4 (37.3−50.4) |
| Y1 | 142 | 129 | 90.8 (84.9−95.0) | 40.1 (33.4−48.0) | |
| Y2 | 130 | 125 | 96.2 (91.3−98.7) | 50.2 (42.1−59.9) | |
| MMR-RIT-3 | D42 | 169 | 153 | 90.5 (85.1−94.5) | 46.1 (39.5−53.8) |
| Y1 | 154 | 139 | 90.3 (84.4−94.4) | 43.9 (36.5−52.9) | |
| Y2 | 141 | 136 | 96.5 (91.9−98.8) | 54.0 (46.1−63.3) | |
| M-M-R II | D42 | 158 | 148 | 93.7 (88.7−96.9) | 55.3 (47.9−63.8) |
| Y1 | 146 | 140 | 95.9 (91.3−98.5) | 57.4 (49.1−67.0) | |
| Y2 | 140 | 134 | 95.7 (90.9−98.4) | 59.2 (50.1−70.0) | |
| Anti-mumps (unenhanced PRN assay) *≥ 4 ED50 | |||||
| MMR-RIT-1 | D42 | 71 | 53 | 74.6 (62.9−84.2) | 11.8 (8.4−16.5) |
| Y1 | 161 | 142 | 88.2 (82.2−92.7) | 33.1 (24.9−44.2) | |
| Y2 | 157 | 144 | 91.7 (86.3−95.5) | 43.4 (33.4−56.3) | |
| MMR-RIT-2 | D42 | 69 | 55 | 79.7 (68.3−88.4) | 17.3 (11.8−25.4) |
| Y1 | 170 | 152 | 89.4 (83.8−93.6) | 40.2 (31.0−52.1) | |
| Y2 | 144 | 134 | 93.1 (87.6−96.6) | 48.9 (37.7−63.5) | |
| MMR-RIT-3 | D42 | 73 | 61 | 83.6 (73.0−91.2) | 16.0 (11.4−22.4) |
| Y1 | 184 | 161 | 87.5 (81.8−91.9) | 42.7 (32.9−55.4) | |
| Y2 | 157 | 152 | 96.8 (92.7−99.0) | 57.4 (45.7−72.2) | |
| M-M-R II | D42 | 82 | 59 | 72.0 (60.9−81.3) | 14.3 (10.3−19.9) |
| Y1 | 167 | 148 | 88.6 (82.8−93.0) | 46.4 (35.7−60.3) | |
| Y2 | 152 | 144 | 94.7 (89.9−97.7) | 60.7 (47.6−77.5) | |
| Anti-rubella antibody ≥10 IU/mL | |||||
| MMR-RIT-1 | D42 | 182 | 180 | 98.9 (96.1−99.9) | 74.3 (66.4−83.1) |
| Y1 | 179 | 177 | 98.9 (96.0−99.9) | 136.4 (121.4−153.3) | |
| Y2 | 171 | 171 | 100 (97.9−100) | 78.0 (69.7−87.2) | |
| MMR-RIT-2 | D42 | 170 | 167 | 98.2 (94.9−99.6) | 74.4 (65.8−84.0) |
| Y1 | 174 | 173 | 99.4 (96.8−100) | 134.8 (121.4−149.8) | |
| Y2 | 158 | 158 | 100 (97.7−100) | 79.5 (71.7−88.2) | |
| MMR-RIT-3 | D42 | 185 | 182 | 98.4 (95.3−99.7) | 67.8 (61.0−75.5) |
| Y1 | 190 | 189 | 99.5 (97.1−100) | 135.6 (122.0−150.7) | |
| Y2 | 168 | 168 | 100 (97.8−100) | 81.7 (73.8−90.4) | |
| M-M-R II | D42 | 178 | 178 | 100 (97.9−100) | 89.6 (80.3−100.0) |
| Y1 | 178 | 178 | 100 (97.9−100) | 165.7 (149.4−183.9) | |
| Y2 | 166 | 166 | 100 (97.8−100) | 93.1 (83.6−103.6) | |
MMR-RIT-1: lot 1 of MMR
MMR-RIT-2: lot 2 of MMR
MMR-RIT-3: lot 3 of MMR
M-M-R II: Merck's MMR vaccine
D42= Post-vaccination blood sample at Day 42
Y1= Antibody persistence blood sample at Year 1
Y2= Antibody persistence blood sample at Year 2
N = number of subjects with available results; n/% = number/percentage of children with concentration above the specified value; 95% CI = 95% confidence interval
GMC= geometric mean antibody concentration calculated on all children
*
Enhanced PRN assay was used in the first year and unenhanced PRN assay was used in the second year